Kamil Bronikowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kamil Bronikowski has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Maksymilian Ryszkowski
Medical University of Warsaw
9 shared publications - Paulina Kawalec
Medical University of Warsaw
9 shared publications - Antoni Klamka
Medical University of Warsaw
8 shared publications - Krystian Fornal
Medical University of Warsaw
8 shared publications - Kinga Krzysztofik
Medical University of Warsaw
7 shared publications - Natalia BęDkowska-Kuśmierek
Medical University of Warsaw
7 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 94, 72962
The Association Between LPR, Obstructive Sleep Apnea, and Asthma - A Narrative Review
Background: Laryngopharyngeal reflux (LPR), obstructive sleep apnea (OSA), and asthma are common disorders increasingly recognized as interconnected conditions sharing inflammatory and mechanical mechanisms. Their coexistence may worsen symptoms and reduce quality of life. Aim: To review current evidence regarding the association between LPR, OSA, and asthma, including shared pathophysiological mechanisms and clinical implications. Material and Methods: A narrative review of meta-analyses, observational studies, and clinical reports examining prevalence, pathophysiology, clinical presentation, and treatment strategies related to LPR, OSA, and asthma. Results: Studies demonstrate a significant overlap among these conditions. LPR is frequently observed in patients with OSA and asthma, while OSA prevalence is increased in asthmatic individuals. Proposed mechanisms include chronic inflammation, obesity, autonomic dysfunction, upper airway instability, and nocturnal hypoxia, creating a bidirectional cycle in which each disorder may aggravate the others. Continuous positive airway pressure (CPAP) therapy may improve reflux symptoms and asthma control, whereas proton pump inhibitor treatment for LPR often provides limited benefit. Conclusions: LPR, OSA, and asthma may represent an overlapping clinical triad rather than isolated diseases. Awareness of their coexistence may improve diagnosis and support multidisciplinary management. Further prospective studies are needed to clarify causal relationships and optimize treatment strategies.
- 16 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 94, 72962
Open AccessThe Association Between LPR, Obstructive Sleep Apnea, and Asthma - A Narrative Review
Background: Laryngopharyngeal reflux (LPR), obstructive sleep apnea (OSA), and asthma are common disorders increasingly recognized as interconnected conditions sharing inflammatory and mechanical mechanisms. Their coexistence may worsen symptoms and reduce quality of life. Aim: To review current evidence regarding the association between LPR, OSA, and asthma, including shared pathophysiological mechanisms and clinical implications. Material and Methods: A narrative review of meta-analyses, observational studies, and clinical reports examining prevalence, pathophysiology, clinical presentation, and treatment strategies related to LPR, OSA, and asthma. Results: Studies demonstrate a significant overlap among these conditions. LPR is frequently observed in patients with OSA and asthma, while OSA prevalence is increased in asthmatic individuals. Proposed mechanisms include chronic inflammation, obesity, autonomic dysfunction, upper airway instability, and nocturnal hypoxia, creating a bidirectional cycle in which each disorder may aggravate the others. Continuous positive airway pressure (CPAP) therapy may improve reflux symptoms and asthma control, whereas proton pump inhibitor treatment for LPR often provides limited benefit. Conclusions: LPR, OSA, and asthma may represent an overlapping clinical triad rather than isolated diseases. Awareness of their coexistence may improve diagnosis and support multidisciplinary management. Further prospective studies are needed to clarify causal relationships and optimize treatment strategies.
- Open Access
- 8 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73065
Large Language Models in Medicine: Opportunities, Limitations, and Future Directions – A Scoping Review
Introduction. Large language models (LLMs) are increasingly used in healthcare and health-related fields, including clinical decision support, personalized medicine, digital health, and sports performance monitoring. However, concerns regarding reliability, transparency, and safety continue to limit their broader implementation. Materials and Methods. A scoping review of 24 PubMed-indexed studies published between 2023 and 2026 was conducted to assess current applications, benefits, limitations, and future directions of LLMs in healthcare. Results. LLMs are being applied in clinical decision support, diagnostics, biomedical research, personalized healthcare, and digital health solutions. They can enhance information retrieval, clinical reasoning, literature synthesis, health monitoring, and sports-related applications such as training support and performance optimization. Emerging trends include retrieval-augmented generation, multimodal systems, and specialized AI agents. Key challenges include hallucinations, limited explainability, privacy concerns, and insufficient clinical validation. Conclusions. LLMs have significant potential to improve healthcare, biomedical research, and health-oriented sports applications. Currently, they should serve as supportive tools rather than autonomous decision-makers. Further progress requires robust validation, regulatory oversight, and effective human–AI collaboration.
- 8 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73065
Open AccessLarge Language Models in Medicine: Opportunities, Limitations, and Future Directions – A Scoping Review
Introduction. Large language models (LLMs) are increasingly used in healthcare and health-related fields, including clinical decision support, personalized medicine, digital health, and sports performance monitoring. However, concerns regarding reliability, transparency, and safety continue to limit their broader implementation. Materials and Methods. A scoping review of 24 PubMed-indexed studies published between 2023 and 2026 was conducted to assess current applications, benefits, limitations, and future directions of LLMs in healthcare. Results. LLMs are being applied in clinical decision support, diagnostics, biomedical research, personalized healthcare, and digital health solutions. They can enhance information retrieval, clinical reasoning, literature synthesis, health monitoring, and sports-related applications such as training support and performance optimization. Emerging trends include retrieval-augmented generation, multimodal systems, and specialized AI agents. Key challenges include hallucinations, limited explainability, privacy concerns, and insufficient clinical validation. Conclusions. LLMs have significant potential to improve healthcare, biomedical research, and health-oriented sports applications. Currently, they should serve as supportive tools rather than autonomous decision-makers. Further progress requires robust validation, regulatory oversight, and effective human–AI collaboration.
- Open Access
- 29 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
REVISITING THE SAFETY PROFILE OF TOPICAL CALCINEURIN INHIBITORS IN ATOPIC DERMATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015–2026) IN THE CONTEXT OF PUBLIC HEALTH REGULATIONS
Background. Atopic Dermatitis (AD) is a widespread, chronic inflammatory-related skin con-dition. Despite the effectiveness of topical calcineurin inhibitors (TCIs), their use is often limited by "TCI phobia" fueled by FDA "black box" warnings regarding potential oncological risks. These warnings were based on animal model studies conducted early in the development of the drug and systemic transplantation data. Aim. The aim of this study is to evaluate the oncological safety of TCIs in patients with atopic dermatitis by synthesizing the latest epidemiological evidence (2015–2026) and to discuss the implications of current public health regulator restrictions. Material and methods. A systematic review and meta-analysis adhered to the PRISMA 2020 guidelines. Databases (PubMed, Embase) were searched for cohort and case-control studies. Ten high-quality studies (Newcastle-Ottawa Scale ≥7) were selected. Statistical analysis was performed using JASP (Version 0.18.3) with a random-effects model (Restricted ML) to calcu-late pooled Relative Risks (RR) and evaluate heterogeneity (I2). Results. The quantitative synthesis included diverse age and geographical cohorts. The analysis revealed that TCI use is not associated with a statistically significant increase in the overall risk of malignancy (pooled RR = 0.97; 95% CI: 0.82–1.15; p = 0.529). Heterogeneity was non-existent (I2 = 0%). Long-term data (e.g., APPLES study) and large-scale pharmacovigilance reports (17 million FAERS records) confirmed no increased risk of lymphomas or hematopoietic malignancies. Conclusions. The oncological safety profile of TCIs is favorable and supported by pharmaco-kinetic evidence, that shows minor systemic absorption (< 1.0 ng/mL). Systemic cancer cases associated with TCI(s) are most likely historically attributed to protopathic bias. These findings strongly supports the removal of the "black box" warnings to reduce "TCI phobia" and improve therapeutic outcomes and quality of life for AD patients.
- 29 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Open AccessREVISITING THE SAFETY PROFILE OF TOPICAL CALCINEURIN INHIBITORS IN ATOPIC DERMATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015–2026) IN THE CONTEXT OF PUBLIC HEALTH REGULATIONS
Background. Atopic Dermatitis (AD) is a widespread, chronic inflammatory-related skin con-dition. Despite the effectiveness of topical calcineurin inhibitors (TCIs), their use is often limited by "TCI phobia" fueled by FDA "black box" warnings regarding potential oncological risks. These warnings were based on animal model studies conducted early in the development of the drug and systemic transplantation data. Aim. The aim of this study is to evaluate the oncological safety of TCIs in patients with atopic dermatitis by synthesizing the latest epidemiological evidence (2015–2026) and to discuss the implications of current public health regulator restrictions. Material and methods. A systematic review and meta-analysis adhered to the PRISMA 2020 guidelines. Databases (PubMed, Embase) were searched for cohort and case-control studies. Ten high-quality studies (Newcastle-Ottawa Scale ≥7) were selected. Statistical analysis was performed using JASP (Version 0.18.3) with a random-effects model (Restricted ML) to calcu-late pooled Relative Risks (RR) and evaluate heterogeneity (I2). Results. The quantitative synthesis included diverse age and geographical cohorts. The analysis revealed that TCI use is not associated with a statistically significant increase in the overall risk of malignancy (pooled RR = 0.97; 95% CI: 0.82–1.15; p = 0.529). Heterogeneity was non-existent (I2 = 0%). Long-term data (e.g., APPLES study) and large-scale pharmacovigilance reports (17 million FAERS records) confirmed no increased risk of lymphomas or hematopoietic malignancies. Conclusions. The oncological safety profile of TCIs is favorable and supported by pharmaco-kinetic evidence, that shows minor systemic absorption (< 1.0 ng/mL). Systemic cancer cases associated with TCI(s) are most likely historically attributed to protopathic bias. These findings strongly supports the removal of the "black box" warnings to reduce "TCI phobia" and improve therapeutic outcomes and quality of life for AD patients.
- Open Access
- 23 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 93
Fecal Calprotectin: Beyond a Biomarker of Intestinal Inflammation
Background.Fecal calprotectin (FC), a neutrophil-derived S100A8/S100A9 heterodimer, is a widely used non-invasive biomarker of intestinal inflammation, particularly in inflammatory bowel diseases (IBD). Emerging evidence suggests its broader role in gut barrier dysfunction and systemic inflammation. Aim.To evaluate the clinical relevance of fecal calprotectin, focusing on its diagnostic performance, limitations, and emerging applications beyond IBD. Material and methods.A narrative review of PubMed-indexed literature was conducted, including original studies and reviews addressing the biological role of calprotectin, its diagnostic accuracy, and its association with intestinal permeability, microbiota, and metabolic inflammation. Results.Fecal calprotectin demonstrates high sensitivity for detecting intestinal inflammation and is useful in differentiating IBD from functional disorders such as irritable bowel syndrome. Its levels correlate with disease activity and are valuable in monitoring treatment response and predicting relapse. However, its specificity is limited, as elevated levels may occur in infections, malignancies, and drug-related mucosal injury. Recent studies suggest associations between FC, gut microbiota alterations, and low-grade systemic inflammation. Conclusions.Fecal calprotectin is a valuable tool in the diagnosis and management of intestinal inflammation. Its expanding role in systemic conditions highlights the need for further research to improve standardization and clarify its clinical applications
- 23 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 93
Open AccessFecal Calprotectin: Beyond a Biomarker of Intestinal Inflammation
Background.Fecal calprotectin (FC), a neutrophil-derived S100A8/S100A9 heterodimer, is a widely used non-invasive biomarker of intestinal inflammation, particularly in inflammatory bowel diseases (IBD). Emerging evidence suggests its broader role in gut barrier dysfunction and systemic inflammation. Aim.To evaluate the clinical relevance of fecal calprotectin, focusing on its diagnostic performance, limitations, and emerging applications beyond IBD. Material and methods.A narrative review of PubMed-indexed literature was conducted, including original studies and reviews addressing the biological role of calprotectin, its diagnostic accuracy, and its association with intestinal permeability, microbiota, and metabolic inflammation. Results.Fecal calprotectin demonstrates high sensitivity for detecting intestinal inflammation and is useful in differentiating IBD from functional disorders such as irritable bowel syndrome. Its levels correlate with disease activity and are valuable in monitoring treatment response and predicting relapse. However, its specificity is limited, as elevated levels may occur in infections, malignancies, and drug-related mucosal injury. Recent studies suggest associations between FC, gut microbiota alterations, and low-grade systemic inflammation. Conclusions.Fecal calprotectin is a valuable tool in the diagnosis and management of intestinal inflammation. Its expanding role in systemic conditions highlights the need for further research to improve standardization and clarify its clinical applications
- Open Access
- 14 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 58, 72649
Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency epidemiology, etiopathogenesis, clinical presentation, treatment – a systematic review
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of the adrenal cortex caused by a deficiency of an enzyme involved in adrenal steroidogenesis. In the majority of cases (95%), this deficiency affects the enzyme 21-hydroxylase. A deficiency or complete absence of enzymes involved in steroidogenesis disrupts the steroidogenic pathways, resulting in increased synthesis of steroid hormone precursors, which leads to an excess of adrenal androgens and virilization in female patients. The aim of this study was to review the current literature on the epidemiology, etiopathogenesis, and clinical presentation of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, as well as to discuss contemporary treatment methods for this condition. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is a complex disorder with a broad clinical spectrum, requiring a multidisciplinary diagnostic and therapeutic approach. The pathophysiology of the disease is based on cortisol and aldosterone deficiency combined with an excess of adrenal androgens, which results in different clinical presentations depending on the patient's age, sex, and the severity of the genetic variant. The implementation of universal newborn screening based on 17OHP measurement has significantly reduced mortality associated with adrenal crisis, particularly in boys, in whom the normal appearance of the external genitalia delayed diagnosis. Replacement therapy with hydrocortisone and fludrocortisone, although effective, does not fully replicate the physiological circadian rhythm of cortisol secretion and is associated with a risk of numerous long-term complications. Therapeutic prospects include CRF receptor antagonists, molecules inhibiting ACTH secretion, and gene therapy, although none of these approaches has yet entered routine clinical practice.
- 14 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 58, 72649
Open AccessCongenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency epidemiology, etiopathogenesis, clinical presentation, treatment – a systematic review
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of the adrenal cortex caused by a deficiency of an enzyme involved in adrenal steroidogenesis. In the majority of cases (95%), this deficiency affects the enzyme 21-hydroxylase. A deficiency or complete absence of enzymes involved in steroidogenesis disrupts the steroidogenic pathways, resulting in increased synthesis of steroid hormone precursors, which leads to an excess of adrenal androgens and virilization in female patients. The aim of this study was to review the current literature on the epidemiology, etiopathogenesis, and clinical presentation of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, as well as to discuss contemporary treatment methods for this condition. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is a complex disorder with a broad clinical spectrum, requiring a multidisciplinary diagnostic and therapeutic approach. The pathophysiology of the disease is based on cortisol and aldosterone deficiency combined with an excess of adrenal androgens, which results in different clinical presentations depending on the patient's age, sex, and the severity of the genetic variant. The implementation of universal newborn screening based on 17OHP measurement has significantly reduced mortality associated with adrenal crisis, particularly in boys, in whom the normal appearance of the external genitalia delayed diagnosis. Replacement therapy with hydrocortisone and fludrocortisone, although effective, does not fully replicate the physiological circadian rhythm of cortisol secretion and is associated with a risk of numerous long-term complications. Therapeutic prospects include CRF receptor antagonists, molecules inhibiting ACTH secretion, and gene therapy, although none of these approaches has yet entered routine clinical practice.
- Open Access
- 7 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 57
Association Between Psoriasis and Hashimoto’s Thyroiditis - A Systematic Review
Background Psoriasis is a chronic immune-mediated inflammatory disease increasingly associated with other autoimmune disorders, including autoimmune thyroid diseases, particularly Hashimoto’s thyroiditis. In recent years, numerous studies have investigated the relationship between psoriasis and thyroid dysfunction; however, the available evidence remains partly inconsistent. Objective The aim of this study was to evaluate the association between psoriasis and autoimmune thyroid diseases based on available observational studies, systematic reviews, and meta-analyses. Methods A literature review was conducted using publications available in PubMed, PMC, Frontiers, and MDPI databases. Observational studies, systematic reviews, meta-analyses, and Mendelian randomization studies investigating the relationship between psoriasis and thyroid diseases were included. Data regarding the prevalence of AITD, thyroid autoantibodies, and thyroid dysfunction in patients with psoriasis were analyzed. Results Available evidence indicates that patients with psoriasis have an increased risk of autoimmune thyroid diseases. In the meta-analysis by Zhang et al., including 253,313 psoriasis patients and 1,376,533 controls, psoriasis was associated with a significantly increased risk of AITD (OR = 1.76; 95% CI: 1.35–2.28), particularly Hashimoto’s thyroiditis (OR = 1.88; 95% CI: 1.50–2.35). Observational studies also demonstrated higher levels of anti-TPO and anti-TG antibodies, more frequent thyroid dysfunction, and ultrasonographic changes suggestive of thyroid autoimmunity among psoriasis patients. Conclusions Psoriasis is associated with an increased prevalence of autoimmune thyroid diseases, especially Hashimoto’s thyroiditis. The observed relationship may result from shared immunological and genetic mechanisms. Further prospective and causal studies are required to better understand the nature of this association.
- 7 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 57
Open AccessAssociation Between Psoriasis and Hashimoto’s Thyroiditis - A Systematic Review
Background Psoriasis is a chronic immune-mediated inflammatory disease increasingly associated with other autoimmune disorders, including autoimmune thyroid diseases, particularly Hashimoto’s thyroiditis. In recent years, numerous studies have investigated the relationship between psoriasis and thyroid dysfunction; however, the available evidence remains partly inconsistent. Objective The aim of this study was to evaluate the association between psoriasis and autoimmune thyroid diseases based on available observational studies, systematic reviews, and meta-analyses. Methods A literature review was conducted using publications available in PubMed, PMC, Frontiers, and MDPI databases. Observational studies, systematic reviews, meta-analyses, and Mendelian randomization studies investigating the relationship between psoriasis and thyroid diseases were included. Data regarding the prevalence of AITD, thyroid autoantibodies, and thyroid dysfunction in patients with psoriasis were analyzed. Results Available evidence indicates that patients with psoriasis have an increased risk of autoimmune thyroid diseases. In the meta-analysis by Zhang et al., including 253,313 psoriasis patients and 1,376,533 controls, psoriasis was associated with a significantly increased risk of AITD (OR = 1.76; 95% CI: 1.35–2.28), particularly Hashimoto’s thyroiditis (OR = 1.88; 95% CI: 1.50–2.35). Observational studies also demonstrated higher levels of anti-TPO and anti-TG antibodies, more frequent thyroid dysfunction, and ultrasonographic changes suggestive of thyroid autoimmunity among psoriasis patients. Conclusions Psoriasis is associated with an increased prevalence of autoimmune thyroid diseases, especially Hashimoto’s thyroiditis. The observed relationship may result from shared immunological and genetic mechanisms. Further prospective and causal studies are required to better understand the nature of this association.
- Open Access
- 7 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 91
Metformin as a Potential Geroprotective Agent: Mechanisms, Clinical Evidence and Implications for Healthy Aging
Background: Population aging represents a major medical and socioeconomic challenge worldwide. The increasing prevalence of age-related diseases, including cardiovascular disorders, neurodegeneration, cancer, and metabolic dysfunction, highlights the need for strategies aimed at extending healthspan rather than lifespan alone. In this context, pharmacological agents that modulate fundamental biological processes of aging have attracted significant attention. Metformin has emerged as a potential candidate beyond its established role in the treatment of type 2 diabetes mellitus. Aim: This narrative review aimed to evaluate current evidence regarding the potential geroprotective properties of metformin, with particular emphasis on underlying molecular mechanisms and available clinical data. Materials and Methods: A narrative literature review was conducted using the PubMed database. Articles published between January 2015 and March 2025 were identified using the keywords “metformin”, “aging”, “longevity”, and “geroprotection”. Peer-reviewed original studies and review articles in English were included, while case reports and non-peer-reviewed publications were excluded. Results: Evidence indicates that metformin influences multiple pathways involved in aging, including activation of AMP-activated protein kinase (AMPK), inhibition of the mechanistic target of rapamycin (mTOR), modulation of mitochondrial metabolism, reduction of oxidative stress, and attenuation of chronic inflammation. Observational studies suggest associations with reduced incidence of age-related diseases and improved survival; however, direct evidence in non-diabetic populations remains limited. Conclusions: Metformin demonstrates properties consistent with potential geroprotective effects. However, well-designed randomized controlled trials are required to confirm its efficacy and safety in the context of healthy aging.
- 7 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 91
Open AccessMetformin as a Potential Geroprotective Agent: Mechanisms, Clinical Evidence and Implications for Healthy Aging
Background: Population aging represents a major medical and socioeconomic challenge worldwide. The increasing prevalence of age-related diseases, including cardiovascular disorders, neurodegeneration, cancer, and metabolic dysfunction, highlights the need for strategies aimed at extending healthspan rather than lifespan alone. In this context, pharmacological agents that modulate fundamental biological processes of aging have attracted significant attention. Metformin has emerged as a potential candidate beyond its established role in the treatment of type 2 diabetes mellitus. Aim: This narrative review aimed to evaluate current evidence regarding the potential geroprotective properties of metformin, with particular emphasis on underlying molecular mechanisms and available clinical data. Materials and Methods: A narrative literature review was conducted using the PubMed database. Articles published between January 2015 and March 2025 were identified using the keywords “metformin”, “aging”, “longevity”, and “geroprotection”. Peer-reviewed original studies and review articles in English were included, while case reports and non-peer-reviewed publications were excluded. Results: Evidence indicates that metformin influences multiple pathways involved in aging, including activation of AMP-activated protein kinase (AMPK), inhibition of the mechanistic target of rapamycin (mTOR), modulation of mitochondrial metabolism, reduction of oxidative stress, and attenuation of chronic inflammation. Observational studies suggest associations with reduced incidence of age-related diseases and improved survival; however, direct evidence in non-diabetic populations remains limited. Conclusions: Metformin demonstrates properties consistent with potential geroprotective effects. However, well-designed randomized controlled trials are required to confirm its efficacy and safety in the context of healthy aging.
- Open Access
- 23 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 90, 70498
The Association Between Sugar-Sweetened Beverage (SSB) Consumption and Gut Microbiota Composition and Related Metabolites in Adults: A Systematic Review
Background. Sugar-Sweetened Beverages (SSB) are a major source of dietary sugars worldwide. Emerging evidence suggests that dietary factors, including sugar intake, may influence the composition of the gut microbiota, which plays a crucial role in human physiology. However, the relationships between habitual SSB intake, gut microbiota composition, and related metabolites in adults remain insufficiently studied. Aim. This systematic review aimed to synthesize available evidence on the associations between SSB consumption, gut microbiota composition, and related metabolite profiles in adults, while identifying methodological differences and gaps in literature. Material and methods. A systematic search identified observational studies investigating SSB intake and gut microbiota or metabolite outcomes in healthy adult populations. Results. Higher SSB intake was consistently associated with alterations in gut microbial composition, including shifts in the Firmicutes: Bacteroidetes ratio. Changes included reductions in short-chain fatty acid producing species including Eubacterium eligens, Ruminococcus callidus, and several Clostridium species. Metabolomic analyses revealed changes in branched-chain amino acids, aromatic amino acids, glycerophospholipids and bile acids with distinct patterns observed for specific SSB types. Overall, 56 serum metabolites were significantly related to SSB intake and implicated in diabetes risk. SSB was also linked to higher visceral adiposity index, total and LDL-cholesterol. Added sugar intake was positively associated with the genus Lachnobacterium. Conclusions. Habitual SSB consumption may influence gut microbial composition and related metabolites in adults, contributing to metabolic dysregulation. The limited number of studies, methodological differences and observational nature of available evidence, highlight the need for interventional studies and the necessity of standardized methods.
- 23 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 90, 70498
Open AccessThe Association Between Sugar-Sweetened Beverage (SSB) Consumption and Gut Microbiota Composition and Related Metabolites in Adults: A Systematic Review
Background. Sugar-Sweetened Beverages (SSB) are a major source of dietary sugars worldwide. Emerging evidence suggests that dietary factors, including sugar intake, may influence the composition of the gut microbiota, which plays a crucial role in human physiology. However, the relationships between habitual SSB intake, gut microbiota composition, and related metabolites in adults remain insufficiently studied. Aim. This systematic review aimed to synthesize available evidence on the associations between SSB consumption, gut microbiota composition, and related metabolite profiles in adults, while identifying methodological differences and gaps in literature. Material and methods. A systematic search identified observational studies investigating SSB intake and gut microbiota or metabolite outcomes in healthy adult populations. Results. Higher SSB intake was consistently associated with alterations in gut microbial composition, including shifts in the Firmicutes: Bacteroidetes ratio. Changes included reductions in short-chain fatty acid producing species including Eubacterium eligens, Ruminococcus callidus, and several Clostridium species. Metabolomic analyses revealed changes in branched-chain amino acids, aromatic amino acids, glycerophospholipids and bile acids with distinct patterns observed for specific SSB types. Overall, 56 serum metabolites were significantly related to SSB intake and implicated in diabetes risk. SSB was also linked to higher visceral adiposity index, total and LDL-cholesterol. Added sugar intake was positively associated with the genus Lachnobacterium. Conclusions. Habitual SSB consumption may influence gut microbial composition and related metabolites in adults, contributing to metabolic dysregulation. The limited number of studies, methodological differences and observational nature of available evidence, highlight the need for interventional studies and the necessity of standardized methods.
- Open Access
- 21 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 54, 70818
BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review of Clinical Efficacy and Safety
Background: BPC-157 and GHK-Cu are synthetic peptides with potential in tissue repair, influencing molecular mechanisms in healing, angiogenesis and inflammation. Objective: This review synthesizes preclinical and clinical research on BPC-157 and GHK-Cu efficacy and safety in wound healing and tissue repair, examining mechanistic pathways and translational potential in clinical and sports medicine. Methods: Literature searches of PubMed, Embase and Cochrane Library included studies on wound healing, tissue regeneration, safety and clinical uses of BPC-157 and GHK-Cu without publication date restrictions. Results: Preclinical studies show BPC-157 promotes skin, tendon, muscle and bone healing via specific signaling pathways and growth factor upregulation. GHK-Cu enhances collagen/elastin synthesis, angiogenesis and fibroblast migration. Limited human trials evaluated BPC-157 for knee pain and IV safety, while GHK-Cu showed promise in skin quality trials. Both appear safe but lack comprehensive RCTs. Conclusion: BPC-157 and GHK-Cu show therapeutic potential in wound healing, though evidence is largely preclinical. Extensive human trials are needed to establish clinical efficacy. This review provides groundwork for future research and highlights safety for sports medicine practitioners.
- 21 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 54, 70818
Open AccessBPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review of Clinical Efficacy and Safety
Background: BPC-157 and GHK-Cu are synthetic peptides with potential in tissue repair, influencing molecular mechanisms in healing, angiogenesis and inflammation. Objective: This review synthesizes preclinical and clinical research on BPC-157 and GHK-Cu efficacy and safety in wound healing and tissue repair, examining mechanistic pathways and translational potential in clinical and sports medicine. Methods: Literature searches of PubMed, Embase and Cochrane Library included studies on wound healing, tissue regeneration, safety and clinical uses of BPC-157 and GHK-Cu without publication date restrictions. Results: Preclinical studies show BPC-157 promotes skin, tendon, muscle and bone healing via specific signaling pathways and growth factor upregulation. GHK-Cu enhances collagen/elastin synthesis, angiogenesis and fibroblast migration. Limited human trials evaluated BPC-157 for knee pain and IV safety, while GHK-Cu showed promise in skin quality trials. Both appear safe but lack comprehensive RCTs. Conclusion: BPC-157 and GHK-Cu show therapeutic potential in wound healing, though evidence is largely preclinical. Extensive human trials are needed to establish clinical efficacy. This review provides groundwork for future research and highlights safety for sports medicine practitioners.
- Open Access
- 24 March 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 53
Systemic Lupus erythematosus - Epidemiology, Etiopathogenesis, Clinical Presentation, Cutaneous Manifestations and Treatment - A Systematic Review
Introduction. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex etiopathogenesis and a highly diverse clinical presentation. The disease may involve multiple organs and systems, including the skin, kidneys, nervous system, and cardiovascular system. One of the characteristic features of the disease course are cutaneous manifestations, which may sometimes be the first symptom and can have important diagnostic value. Aim of the study. The aim of this study was to review the current literature on the epidemiology, etiopathogenesis, clinical presentation, and cutaneous manifestations of systemic lupus erythematosus, as well as to discuss contemporary treatment methods for this disease. Conclusions. Systemic lupus erythematosus is a disease of multifactorial etiology in which genetic, immunological, and environmental factors play an important role. The clinical presentation is highly heterogeneous, and skin lesions are among the most common and characteristic manifestations of the disease. Early diagnosis and appropriately selected treatment, including antimalarial drugs, glucocorticosteroids, immunosuppressive agents, and biological therapies, may significantly reduce disease activity and improve patients’ quality of life. Comprehensive management, including prevention of complications and appropriate multidisciplinary care, is also of great importance.
- 24 March 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 53
Open AccessSystemic Lupus erythematosus - Epidemiology, Etiopathogenesis, Clinical Presentation, Cutaneous Manifestations and Treatment - A Systematic Review
Introduction. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex etiopathogenesis and a highly diverse clinical presentation. The disease may involve multiple organs and systems, including the skin, kidneys, nervous system, and cardiovascular system. One of the characteristic features of the disease course are cutaneous manifestations, which may sometimes be the first symptom and can have important diagnostic value. Aim of the study. The aim of this study was to review the current literature on the epidemiology, etiopathogenesis, clinical presentation, and cutaneous manifestations of systemic lupus erythematosus, as well as to discuss contemporary treatment methods for this disease. Conclusions. Systemic lupus erythematosus is a disease of multifactorial etiology in which genetic, immunological, and environmental factors play an important role. The clinical presentation is highly heterogeneous, and skin lesions are among the most common and characteristic manifestations of the disease. Early diagnosis and appropriately selected treatment, including antimalarial drugs, glucocorticosteroids, immunosuppressive agents, and biological therapies, may significantly reduce disease activity and improve patients’ quality of life. Comprehensive management, including prevention of complications and appropriate multidisciplinary care, is also of great importance.